Jørgen Søberg Petersen

Jørgen Søberg Petersen is a Senior Partner at Novo Holdings since September 2017, with extensive experience in the biotechnology and pharmaceutical sectors through various leadership roles, including Partner and Venture Partner. Currently, Jørgen serves as a Non-Executive Director for several companies, including AnaCardio, Antag Therapeutics, Breye Therapeutics ApS, Engimmune Therapeutics, Hemab, Tribune Therapeutics, and previously for Amolyt Pharma and VectivBio AG. Notable achievements include pioneering drug development initiatives in heart failure, obesity, and rare diseases, along with serving as Chairman of the Board at Acesion Pharma where significant financing and clinical advancements occurred. Jørgen holds multiple degrees in medicine, pharmacology, and innovation management from esteemed institutions, complemented by executive training in various business domains.